PTC Therapeutics

PTCT NASDAQ
45.57
-0.89
-1.92%
交易中 10:20 08/22 EDT
开盘
46.42
昨收
46.46
最高
46.49
最低
45.56
成交量
1.12万
成交均量(3M)
56.53万
52周最高
48.99
52周最低
27.53
换手率
0.02%
市值
26.86亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供PTC Therapeutics PTCT股票价格,PTC Therapeutics股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
展开 >

最近浏览

名称
价格
涨跌幅